top of page

GPCR News 

Post: Blog2_Post

Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has...

November 2021


Addex's strategic partner The Janssen Pharmaceutical Companies of Johnson & Johnson, Inc. has completed Phase 1 studies in Japan with JNJ-40411813 (ADX71149)


"Geneva, Switzerland, November 15, 2021 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today announced that Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has successfully completed Phase 1 studies in Japan with JNJ-40411813 (ADX71149). ADX71149 is a selective metabotropic glutamate type 2 (mGlu2) receptor positive allosteric modulator (PAM). The successful completion of this Phase 1 safety program will enable centers in Japan to be included in a potential global development of ADX71149 for the treatment of epilepsy. "



Recent Posts

See All

Amgen to Acquire Chemocentryx for $4 Billion in Cash

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin

Комментарии